Summer 2001

Sharon Swanson, Editor

CANCER RESEARCH FOUNDATION

The Mission of The Cancer Research Foundation Is To Help Find The Cures For Cancer Through Funding Laboratory and Clinical Research.

Connections

WITH FRIENDS

"This is probably the most exciting time in the history of the war on cancer," says Richard L. Schilsky, M.D., associate dean for clinical research in the University of Chicago Biological Sciences Division, and medical consultant to the Cancer Research Foundation.

Research is shaping our future. Of the 1.2 million Americans who will be diagnosed with cancer this year, the number of cancer survivors will continue to climb – because of the dedicated work of cancer researchers.

This year, in the United States, there are hundreds of potential new drug compounds being developed to fight cancers, double the number only five years ago. Before new cancer therapies are made available to the public, they must be proven effective in clinical trials.

Clinical trials in the United States are administered by the Cancer and Leukemia Group B (CALGB), a national clinical research group sponsored by the National Cancer Institute. The Central Office is headquartered at the University of Chicago, and chaired by our medical consultant, Dr. Richard L. Schilsky. CALGB is a national network of 29 university medical centers, over 185 community hospitals and 3,000 physicians who collaborate in clinical research studies.

Here in Chicago, as a part of a current clinical trial, Dr. Schilsky is treating a patient with stomach-lining tumors with a new drug that seeks out tumor cells and delivers an anti-cancer drug. Dr. Nicholas Vogelzang, Director of the University of Chicago Cancer Research Center, is treating a kidney cancer patient using adult stem cells from the patient's sibling. Dr. Thomas Gajewski of the University of Chicago is treating patients with metastatic melanoma, a deadly form of skin cancer, in a clinical trial using a cancer vaccine. Thousands of cancer patients in Chicago, and all over the United States and the World, are currently participating in clinical trials which will lead to the approval of new and more powerful cancer therapies.

Basic research remains the cornerstone of our ability to make progress in all areas of cancer prevention, treatment and cure. Basic research, such as that supported by the Cancer Research Foundation for over 50 years, supplies the basis for clinical advances.

In the future, medical goals include developing a fingerprint of cancer in a particular patient, and designing anti-cancer drugs especially created to attack and eradicate a specific individual cancer without devastating side-effects, moving research progress from the bench to the bedside. Lance Armstrong, a cancer survivor who recently won the Tour de France for the third consecutive year, talks about his son, whose doctors will develop his molecular profile, so that, if necessary, any cancer can be identified and treated before he would even know he had it. Lance Armstrong's son and all young children will grow into adults in a world where cancer is just another chronic disease. A mighty and worthy goal of research.

Merle Goldblatt Cohen
President

"The first wealth is health."

Ralph Waldo Emerson

Michael Riordan Appointed President and CEO University of Chicago Hospitals and Health System

Michael C. Riordan has been appointed President and Chief Executive Officer of the University of Chicago Hospitals and Health System, effective July 1, 2001. Since May of 2000, Mr. Riordan has served as Executive Vice President and CEO.

He replaces Ralph W. Muller, who served as President of the University of Chicago Hospitals since 1986.

U.S. News and World Report names the University of Chicago Hospitals as one of the "Best of the Best" hospitals in the United States

The only hospital in Illinois ever to be named one of the "Best of the Best," the University of Chicago Hospitals is cited as providing a degree of specialized care few community hospitals can match. This expertise is worth seeking out when quality of life, or life itself, is threatened. *U.S. News and World Report* ranked teaching hospitals affiliated with medical schools.

The University of Chicago Comer Children's Hospital

Gary Comer, founder of Lands' End Inc., and his wife, Frances, have donated $21 million toward the cost of building a new children's hospital at the University of Chicago. The new patient rooms will be designed with the needs of the young patients and their families as a primary consideration:

Each new room will be larger, have more windows and personal bulletin boards, large TVs, internet-connected computers, adjustable shower-controls and room temperature controls. The patients will be allowed to wear hospital scrubs instead of embarrassing gowns, and they can select their own bed linens. In the commonly shared areas, there will be personal kitchens and a food court.

Comer Children's Hospital will provide the best possible setting for superb patient care, pediatric research and training. Construction will begin this fall, and should be completed in 2004.



Pediatric Cancer at the University of Chicago

The Pediatric Hematology/Oncology program is a leader in Chicago, offering both conventional and investigational forms of therapy. The program is focused on providing the best possible care for patients; whenever possible, children receive treatments on an outpatient basis.

Each patient is followed by a faculty physician, a Clinical Nurse Specialist, a pediatric oncology social worker and a team of child-life specialists.

The program has specific clinical and research programs in childhood cancer including leukemia, Hodgkin's and non Hodgkin's lymphoma, brain tumors, soft tissue and bone sarcoma. Diagnosis and treatment is provided for all blood diseases. The bone marrow transplantation program is a major regional center in the U.S.

The section of Pediatric Hematology/Oncology has an active and productive clinical research program. As members of the Children's Cancer Group, the section has 160 patients enrolled in 84 protocols. The focus of the pediatric cancer research program is to investigate the process of intercellular communication, which could lead to a better understanding of how to control the growth of cancerous cells.

CANCER RESEARCH FOUNDATION Young Inve

Maria Alegre, M.D., Ph.D.
Assistant Professor
Department of Medicine

ROLE OF NF-kB ACTIVATION IN CTLA4 SIGNALING – $50,000

The immune system with its white blood cells is in charge of destroying cancerous cells as they arise, and prevents the development of full-blown tumors in the majority of people. This process is called "immune surveillance." The most important type of white blood cell for this purpose is called T lymphocyte.

The duration of activation of any given T cell is finite, whether the cancerous cell has been destroyed or not, and in some cases T cells rest before complete elimination of the transformed cells.

Dr. Alegre's research project focuses on trying to prolong the activation state of T lymphocytes, preventing them from going back to a resting state, and maximizing their capacity to fight even grown tumors.

John Crispino, Ph.D.
Assistant Professor
The Ben May Institute for Cancer Research

THE ROLE OF LMO2 IN T-CELL LEUKEMIA – $50,000

Blood is composed of many different types of cells that perform special functions in the human body. Red blood cells carry oxygen to tissues, white cells provide immunity to infections and disease, and platelets control bleeding. The human body constantly replenishes its supply of blood cells in a process call hematopoiesis.

Every type of cell is distinguished by its specific pattern of gene expression: Red blood cells "turn on" genes that make proteins important in oxygen transport, such as hemoglobin. White blood cells "turn off" expression of these genes but "turn on" others important in the immune response, such as antibodies. Transcription factors comprise the molecular machinery that regulates the turning on and off of specific genes.

Leukemias typically arise when certain transcription factors, which are not normally expressed within white blood cells, are turned on. Dr. Crispino's research will be to study the mechanism by which these aberrantly expressed factors cause uncontrolled proliferation and cancer.

Tong Chuan He, M.D., Ph.D.
Assistant Professor of Surgery
Director,
Molecular Oncology Laboratory

IDENTIFICATION OF POTENTIAL THERAPEUTIC PEPTIDES FOR HUMAN OSTEOSARCOMA – $50,000

Osteosarcoma is the most common primary malignant tumor of bone. The peak of age incidence is usually during the second decade of life. conventional treatment for osteosarcoma involves preoperative chemotherapy followed by surgical removal of tumors. Nevertheless, osteosarcoma has a high frequency of recurrence and metastasis.

Dr. He's goal is to develop therapeutic agents for human osteosarcoma. His research plan is to create and direct a new molecular oncology laboratory, which will focus on: 1) the molecular genetic studies of soft tissue sarcomas in search for potential tumor suppressor genes, 2) identification of potential osteosarcoma tumor markers for novel diagnostic and/or therapeutic strategies, and 3) the development of genetic and/or novel therapy for other bone-related diseases.

estigator Awards

Karen Frank, M.D., Ph.D.
Assistant Professor
Department of Pathology

REGULATION OF DNA LIGASE IV IN V(D)J RECOMBINATION AND DNA REPAIR – $50,000

In honor and fond memory of Dr. John E. Ultmann, Dr. Karen Frank is named the Dr. John E. Ultmann Young Investigator.

Dr. Frank's research involves the study of 1) maintaining a normal immune system and 2) the repair of DNA damage.

The first process involves the generation of antibodies that all individuals require to fight infections. During the process of making antibodies, the DNA is broken and rearranged in a controlled manner in white blood cells. If there is an error during this rearrangement of DNA, the incorrectly joined genes can lead to the development of leukemia or lymphoma.

The second process involves the study of DNA repair. DNA in any cell, not just blood cells, can be damaged from exposure to radiation or environmental chemicals, or from the products of metabolism. These DNA breaks are potentially harmful to the cell and must be repaired for the cell to survive. When errors occur in repairing these DNA breaks, abnormal genes that are formed can lead to the development of cancer in any organ.

S. Diane Yamada, M.D.
Assistant Professor
Department of Obstetrics and Gynecology

EVALUATION OF MKK4 AS A METASTASIS SUPPRESSOR GENE IN OVARIAN CARCINOMA– $49,999

Ovarian cancer remains the most lethal gynecologic malignancy. The majority of ovarian cancer patients will develop and die of chemoresistant disease.

Dr. Yamada's research focuses on the regulation of tumor spread in ovarian cancer. Her preliminary data reveals that the expression of a particular protein (MKK4) is absent in perpetually growing ovarian cancer cell lines. She postulates that the restoration of this protein will suppress metastatic growth.

Each year, the Cancer Research Foundation accepts grant requests from young men and women engaged in first-project laboratory and/or clinical cancer research. These proposals come to the Foundation already reviewed and ranked by a faculty awards committee, using the National Institutes of Health peer review process. Only the innovative and bold proposals with practicable research plans are considered for funding.

After receipt by the Foundation, our medical consultants, Dr. Joseph B. Kirsner and Dr. Richard L. Schilsky, interpret the complex science to the trustees. Cancer Research Foundation trustees make all funding decisions.

Last October, five young scientists from the University of Chicago Medical Center were awarded young investigator grants:

- **Maria Alegre, M.D., Ph.D.**
- **John Crispino, Ph.D.**
- **Karen Frank, M.D., Ph.D.**
- **Tong Chuan He, M.D., Ph.D.**
- **S. Diane Yamada, M.D.**

These awards are for one year. At the end of the year, if the hypotheses have proven worthy of further study this early research will be used as a basis for application for major outside funding.

Contribution to the Cure

Please Join Us As We Celebrate
Cynthia's 40th Birthday and the kick-off to her
"Contribution To The Cure"
Fundraising campaign
On November 10th, 2000 at 7:30 in the evening

Hors d'oeuvres, cocktails and
Live music will be provided.
Dress attire is professed.

In lieu of gifts,
Please bring a monetary contribution to
The "Cancer Research Foundation".

Cynthia Brick was tired of losing family members and friends to cancer.

Last year, Cynthia's friend, John died.

Another friend, John, died.
And another friend, Danny, died.

Cynthia's grandmother died at age 39 in 1935.

Cynthia's sister, Keren, died at age 42.

Cynthia's dad died that same year: 1984.

Cynthia's mom, Helen, died in 1990.

Cynthia's sister, Cathryn died in 1996.

She decided to do something about it.

On her 40th birthday, Cynthia had a big party. Good friends, good food, good music. and a good cause. She invited her friends to bring money to fund cancer research. And they did. Cynthia raised $5,160.00, which is being used to fund cancer research.

HOLIDAY CARDS ALL OCCASION CARDS



Yes, we have all the cards you can use. Our 2001 holiday cards will be available soon. For a catalog and ordering instructions, call our office at 312-630-0055 or e-mail us at crf@cancerresearchfdn.org.

Information is on Your Computer.

The National Cancer Institute (NCI) puts information about its State-of-the-Science meetings on a Web site: http://www.conference-cast.com/webtie/sots/sots.htm. The meetings bring together small groups of clinical and basic scientists from industry, academia, the community, as well as patient advocates, for discussions on future clinical research opportunities.

Digital audio makes it possible to hear the presentations while viewing slides and then to listen to the discussions that follow.

Special Occasion and Memorial Acknowledgement

Gifts honoring the memory of someone dear who has died, or gifts in celebration of birthdays, anniversaries, a new home, a new baby or many other special occasions arrive at the Cancer Research Foundation daily.

This represents a current philanthropic trend in gift giving. Caring individuals and companies are making donations to CRF in someone's name, in lieu of client or staff gifts. It's truly a way to demonstrate that it is better to give than to receive.

Now it's even easier to give. In addition to personal checks and cash, **you can charge your gift to VISA, MasterCard or American Express** - by mail, by phoning our office at (312) 630-0055, or online.

Online donations to the Cancer Research Foundation are run on a Secure E-Commerce Transaction Server. When you enter information on our website donation page, the information is encrypted before it gets sent over the Internet.The transaction remains 100% secured from everyone except you, the donor, and CRF.

For further information, contact the Cancer Research Foundation at (312) 630-0055 or visit our website at www.cancerresearchfdn.org.

This Year You Can...

Give To The Cancer Research Foundation Through Payroll Deductions:

Combined Federal Campaign (CFC)
State Of Illinois Campaign
Cook County Campaign
City Of Chicago Campaign
Campaigns Managed By United Way
Corporate Campaigns

The Cancer Research Foundation Is Listed In The Alphabetical Index With A Code Number

If We Are Not Listed, You Can Write Cancer Research Foundation In The "Donor Option" Section

Research: The Best Hope Against Cancer

CANCER RESEARCH FOUNDATION

Office: 135 S. LaSalle St., Suite 2020 ▪ Correspondence: P.O. Box 0493, Chicago, IL 60690-0493
312.630.0055 ▪ Fax: 312.630.0075 ▪ website: http//www.cancerresearchfdn.org

In Memory of
Dr. John E. Ultmann

Founder and Director of the Cancer Research Center
at The University of Chicago 1973-1991



Newsletter Design and Mail Fulfillment by: Executive Services & MailHouse, (630) 663-9808
Professional Photography by: Vanek and Associates (708) 636-9234

Cancer Research Foundation

As a responsible member of the community, the Cancer Research Foundation believes in accountability. We think the more you know about our trustworthy stewardship of funds, the more willing you will be to invest in the future through the Cancer Research Foundation.

Every year, the Cancer Research Foundation files a report with the Internal Revenue Service, IRS Form 990 (Return of Organizations Exempt from Income Tax). This report is available for public inspection in our office. We also make it available by mail, at a nominal cost.

Cancer Research Foundation financial records are audited annually by Grant Thornton. Their report is reprinted in its entirety and included each year in one of our newsletters.

The Cancer Research Foundation is an Illinois 501 (C) (3) not for profit corporation, operating in Chicago. Our mission is to help find the cures for cancer through research.We welcome memorial contributions and gifts in honor of special celebrations. Contributions are deductible to the full extent allowed by law.